This therapeutic strategy employs molecular glue technology to recruit TDP-43 protein aggregates to the cereblon (CRBN) E3 ubiquitin ligase complex, leading to targeted degradation via the proteasome. This approach represents a novel mechanism for directly clearing TDP-43 pathology, which is the hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD-TDP). Unlike antisense oligonucleotides (ASOs) that reduce TDP-43 expression, molecular glues can selectively degrade pathological aggregated forms while preserving essential nuclear TDP-43 function[@rascncarcova2024][@kim2024].
Target
Primary Target: TDP-43 protein aggregates (cytoplasmic inclusions) including C-terminal fragments (CTFs, 25 kDa and 35 kDa species) and phosphorylated TDP-43 (pSer409/410) aggregates
E3 Ligase: CRBN (cereblon) - the same target exploited by immunomodulatory imide drugs (IMiDs)
Expression: TDP-43 is ubiquitously expressed with high neuronal expression; pathological aggregation primarily affects motor neurons, cortical neurons, and hippocampal neurons
Mechanistic Rationale
...
Molecular Glue for TDP-43 Aggregate Clearance
Overview
This therapeutic strategy employs molecular glue technology to recruit TDP-43 protein aggregates to the cereblon (CRBN) E3 ubiquitin ligase complex, leading to targeted degradation via the proteasome. This approach represents a novel mechanism for directly clearing TDP-43 pathology, which is the hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD-TDP). Unlike antisense oligonucleotides (ASOs) that reduce TDP-43 expression, molecular glues can selectively degrade pathological aggregated forms while preserving essential nuclear TDP-43 function[@rascncarcova2024][@kim2024].
Target
Primary Target: TDP-43 protein aggregates (cytoplasmic inclusions) including C-terminal fragments (CTFs, 25 kDa and 35 kDa species) and phosphorylated TDP-43 (pSer409/410) aggregates
E3 Ligase: CRBN (cereblon) - the same target exploited by immunomodulatory imide drugs (IMiDs)
Expression: TDP-43 is ubiquitously expressed with high neuronal expression; pathological aggregation primarily affects motor neurons, cortical neurons, and hippocampal neurons
Mechanistic Rationale
TDP-43 (TARDBP (TAR DNA-binding protein 43)) is a 414-amino acid RNA-binding protein that primarily localizes to the nucleus where it regulates RNA splicing, stability, and transport. In ALS and FTD-TDP, TDP-43 mislocalizes to the cytoplasm where it forms insoluble aggregates that disrupt RNA metabolism, mitochondrial function, and proteostasis. Critically, 97% of ALS cases and ~50% of FTD cases exhibit TDP-43 pathology[@mackenzie2023][@brettschneider2022].
Molecular glues work by simultaneously binding to a target protein and an E3 ligase, bringing them into proximity and inducing ubiquitination and subsequent proteasomal degradation of the target. The CRBN E3 ligase is particularly attractive because:
Validated safety profile: CRBN modulators like lenalidomide and pomalidomide are FDA-approved for multiple myeloma
Molecular glues offer advantages over ASOs by selectively targeting the pathological aggregated form while preserving essential nuclear TDP-43 function. This addresses a key limitation of ASO approaches, which reduce both pathological and functional TDP-43.
Implementation Roadmap
Phase 1: Discovery (Year 1-2)
Activities: Compound library screening, hit validation, SAR optimization
Deliverables: 3-5 lead candidates with in vitro efficacy
[Rascón-Carcova et al., Molecular glue degradation: new paradigm for targeted protein degradation (2024), Rascón-Carcova et al., Molecular glue degradation: new paradigm for targeted protein degradation (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)
[Kim et al., CRBN molecular glues for neurodegenerative disease (2024), Kim et al., CRBN molecular glues for neurodegenerative disease (2024) (2024)](https://doi.org/10.1016/j.tips.2024.06.012)
[Mackenzie et al., TDP-43 pathology in neurodegenerative diseases (2023). Mackenzie et al., TDP-43 pathology in neurodegenerative diseases (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Brettschneider et al., TDP-43 pathology in ALS and FTD (2022). Brettschneider et al., TDP-43 pathology in ALS and FTD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)
[Foley et al., Phospho-TDP-43 as a biomarker in ALS (2023), Foley et al., Phospho-TDP-43 as a biomarker in ALS (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37098234/)
[Gendron et al., Cereblon modulators for protein aggregation diseases (2023), Gendron et al., Cereblon modulators for protein aggregation diseases (2023) (2023)](https://doi.org/10.1038/s41582-023-00789-1)
[Taylor et al., ALS drug development pipeline 2024, Taylor et al., ALS drug development pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38452109/)